ARTICLE | Clinical News
Akynzeo netupitant/palonosetron regulatory update
June 15, 2015 7:00 AM UTC
The European Commission approved Akynzeo netupitant/palonosetron to prevent acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy or moderately emetogenic cancer chemotherapy. The product is a fixed-dose combination of 300 mg netupitant, a neurokinin 1 (NK1) substance P receptor antagonist, and 0.5 mg palonosetron, a selective serotonin (5-HT3) receptor antagonist. ...